Skip to main content

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Laila Asskour

Institutions of which they are part

Research technician
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

Assessing the role of glial cells in migraine and its chronification

IP: Marta Vila Pueyo
Collaborators: Laila Asskour , Victor José Gallardo Lopez, Erika Ivanna Araya
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 175000
Reference: PID2022-137287NA-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Biomarcadores neuroinflamatorios en pacientes con migraña: prueba de concepto para el diagnóstico molecular de la enfermedad

IP: Marta Vila Pueyo
Collaborators: Laila Asskour , Patricia Pozo Rosich, Victor José Gallardo Lopez, Otilia Gliga
Funding agency: Fundación Eugenio Rodríguez Pascual
Funding: 24990
Reference: FERP-2023-MVP
Duration: 17/01/2024 - 16/01/2026

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 31/12/2025

BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña (Estudio MAMBO).

IP: Marta Torres Ferrús
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01530
Duration: 01/01/2023 - 31/12/2025

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
José Antonio Navarro Sanchís

José Antonio Navarro Sanchís

Psychiatry, Mental Health and Addictions
Read more
Ester Palacio Gutierrez

Ester Palacio Gutierrez

Liver Diseases
Read more
Susana Anton Calvo

Susana Anton Calvo

Administration and Management
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.